Gould Asset Management LLC CA grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 10.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,345 shares of the company’s stock after purchasing an additional 315 shares during the quarter. Gould Asset Management LLC CA’s holdings in Johnson & Johnson were worth $591,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Ieq Capital LLC raised its holdings in Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares in the last quarter. Duality Advisers LP purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $4,342,000. Modera Wealth Management LLC grew its position in shares of Johnson & Johnson by 18.0% in the 4th quarter. Modera Wealth Management LLC now owns 44,189 shares of the company’s stock worth $7,806,000 after buying an additional 6,738 shares during the period. RFG Advisory LLC grew its position in shares of Johnson & Johnson by 2.7% in the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares during the period. Finally, Willis Investment Counsel grew its position in shares of Johnson & Johnson by 0.4% in the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after buying an additional 1,358 shares during the period. 67.94% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on JNJ shares. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Raymond James cut their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. SVB Leerink cut their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter in the prior year, the business earned $2.67 EPS. The business’s quarterly revenue was up 5.6% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.99%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Calculate Stock Growth
- 7 Best Retail Stocks to Invest in
- 3 Home Improvement Stocks to Renovate Your Portfolio
- Beam Global Shines Brightly in the EV Infrastructure Space
- Canoo Bottoms As Production Ramp Gets CloserÂ
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
